Carson Advisory’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-22,550
Closed -$35.9K – 181
2024
Q1
$35.9K Hold
22,550
– – 0.03% 173
2023
Q4
$19.4K Buy
22,550
+6,700
+42% +$5.88K 0.02% 159
2023
Q3
$17K Buy
+15,850
New +$32.8K 0.01% 149

Carson Advisory's NGM Position: Q2 2024 in Review

Carson Advisory sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 22,550 shares — an estimated $35.9K sold.

Carson Advisory first reported a position in NGM in Q3 2023 and held it in 3 quarters. The position peaked at $35.9K in Q1 2024. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.

  • Carson Advisory reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Carson Advisory sold 22,550 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $35.9K.
  • Carson Advisory first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2023 and held it in 3 quarters.
  • Carson Advisory's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $35.9K in Q1 2024.
  • 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Carson Advisory's 13F filing for Q2 2024, filed 7 Aug 2024.